Nektar Therapeutics provided earnings guidance for the year 2022. For the year, the company GAAP revenue is unchanged and expected to be between $85 million and $95 million, which includes $15 million to $20 million of product sales and $70 million to $75 million of noncash royalties.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9342 USD | +5.55% | +4.11% | +65.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.35% | 172M | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock Nektar Therapeutics - Nasdaq
- News Nektar Therapeutics
- Nektar Therapeutics Provides Earnings Guidance for the Year 2022